Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid glycoprotein (AGP) and is primarily metabolized by cytochrome P450...

Descripción completa

Detalles Bibliográficos
Autores principales: De Zwart, Loeckie, Snoeys, Jan, Jacobs, Frank, Li, Lilian Y., Poggesi, Italo, Verboven, Peter, Goris, Ivo, Scheers, Ellen, Wynant, Inneke, Monshouwer, Mario, Mamidi, Rao N. V. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452301/
https://www.ncbi.nlm.nih.gov/pubmed/34273250
http://dx.doi.org/10.1002/psp4.12682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452301/
https://www.ncbi.nlm.nih.gov/pubmed/34273250
http://dx.doi.org/10.1002/psp4.12682

Ejemplares similares